Drug Trial Radar · NCT07074327
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Jul 11, 2025
Primary completion
Feb 20, 2026
Study completion Feb 27, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Jul 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407Drug
Suspension for oral administration.
LNG/EEDrug
Combination Tablets for Oral Administration.
NGM/EEDrug
Combination Tablets for Oral Administration.
NET/EEDrug
Combination Tablets for Oral Administration.
DRSP/EEDrug
Combination Tablets for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Observed Plasma Concentration (Cmax) of LNG and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
- Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
- Part B (Optional): Cmax of Norelgestromin (NGMN) and Norgestrel (NG) (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
- Part B (Optional): AUC0-inf of NGMN and NG (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
- Part C (Optional): Cmax of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
- Part C (Optional): AUC0-inf of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
- Part D (Optional): Cmax of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
- Part D (Optional): AUC0-inf of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences - Kansas City
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.